|
NCEs Outside the Scope of Sec. 3(d), Efficacy Data not Required - II |
|
Montag, 30. August 2010 um 16:19 Uhr |
|
Continued from our last post where we briefly discussed about the rejection of pre-grant opposition filed by Cipla for the Application Number 3003/CHENP/2004 for anti-cancer drug Nilotinib which Zum Artikel:
|
|
NCEs Outside the Scope of Sec. 3(d), Efficacy Data not Required - I |
|
Samstag, 21. August 2010 um 15:09 Uhr |
|
Patent Circle earlier posted the issuance of Indian Patent Number 237430 to Novartis against the Application Number 3003/CHENP/2003 for anticancer drug Nilotinib, globally marketed as Tasigna. Like Zum Artikel:
|
|
Aurobindo and Torrent loses Uroxatral patent lawsuit |
|
Freitag, 20. August 2010 um 14:47 Uhr |
|
Judge Gregory Sleet of the US District Court for the District of Delaware lately decided in favor of Sanofi-Aventis in Uroxatral patent lawsuit and ruled that Sanofi’s US Patent Number 4,661,491 is Zum Artikel:
|
|
Patent Circle on Facebook and Twitter |
|
Freitag, 20. August 2010 um 10:55 Uhr |
|
We are extremely happy to be back to blogging after a considerable time gap. Last 10-12 months had been very busy and hectic for us as well as the memorable time of our life as Seema and I became Zum Artikel:
|
|
Mylan generic Mirapex violates Boehringer’s patent |
|
Freitag, 20. August 2010 um 13:42 Uhr |
|
Judge Faith S. Hochberg of the District Court of the District of New Jersey lately ruled in the favor of Boehringer Ingelheim and found Boehringer’s US Patent Number 4,886,812 infringed and Zum Artikel:
|
|
Cipla knocks down key patent blocking i-pill |
|
Donnerstag, 19. August 2010 um 23:33 Uhr |
|
In another post-grant opposition decided earlier this month, the Mumbai Patent Office revoked Indian Patent Number 202297 issued to Richter Gedon protecting emergency contraceptive pill containing Zum Artikel:
|
|
Novartis loses DULERA patent in India |
|
Donnerstag, 19. August 2010 um 22:12 Uhr |
|
Earlier this month, the Swiss Multinational Novartis lost DULERA post-grant opposition to Mumbai-based Cipla as the Chennai Patent Office revoked Indian Patent Number 202350 on the ground of Zum Artikel:
|
|
Mittwoch, 02. Juni 2010 um 15:54 Uhr |
|
One of the finest scientists India ever produced – APJ Abdul Kalam urges Indian scientists to become pioneers in innovation and technology in his recent speech at the Tata Institute of Fundamental Zum Artikel:
|
|
Novartis Sues Macleods Over Famciclovir Patent |
|
Dienstag, 20. April 2010 um 16:02 Uhr |
|
Novartis has lately filed a civil lawsuit against the Mumbai-based generic manufacturer Macleods Pharmaceuticals Limited for infringement of US Patent No. 5,866,581 listed with the Orange Book for Zum Artikel:
|
|
Piramal acquired i-pill from Cipla |
|
Samstag, 03. April 2010 um 17:44 Uhr |
|
Lately Cipla sold its money-spinning contraceptive brand product “i-pill” to Piramal Healthcare for INR. 95 crores. I-pill is an emergency contraceptive pill containing 1.5mg of Levonorgestrel Zum Artikel:
|
|
|
|
|
<< Start < Zurück 1 2 3 4 5 6 Weiter > Ende >>
|
|
Seite 1 von 6 |
Feed Entries